Immunosuppression in pediatric liver and intestinal transplantation: a closer look at the arsenal.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Pediatric Gastroenterology and Nutrition - JPGN

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.MPG.0000172260.46986.11PMID 16056093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mycophenolate mofetil

  2019cited by this paper
• Basiliximab

  2012cited by this paper
• C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral® Formulation

  2012cited by this paper
• A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation

  2004cited by this paper
• Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range

  2004cited by this paper
• Present experience with Campath‐1H in organ transplantation and its potential use in pediatric recipients

  2004cited by this paper
• The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

  2004cited by this paper
• Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients

  2003cited by this paper
• A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection

  2003cited by this paper
• Cyclosporine absorption profiles in pediatric kidney and liver transplant patients

  2003cited by this paper
• Liver and intestine transplantation

  2003cited by this paper
• Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

  2003cited by this paper
• Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications

  2003cited by this paper
• Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience1

  2003cited by this paper
• Steroid withdrawal after pediatric liver transplantation: a long-term follow-up study in 109 recipients.

  2003cited by this paper
• Steroid-free liver transplantation in children.

  2003cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

  2003cited by this paper
• Neoral monitoring 2 hours post‐dose and the pediatric transplant patient

  2003cited by this paper
• Experiences with leflunomide in solid organ transplantation.

  2002cited by this paper
• Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants.

  2002cited by this paper
• Sirolimus-based immunosuppresive protocol for calcineurin sparing in liver transplantation

  2002cited by this paper
• Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results.

  2002cited by this paper
• Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids.

  2002cited by this paper
• Use of calcineurin inhibitors in pediatric liver transplantation: a single-center experience.

  2002cited by this paper
• Experience with the use of basiliximab in liver transplantation--use in pediatric and adult recipients in combination with cyclosporine or tacrolimus.

  2002cited by this paper
• Concomitant basiliximab with low‐dose calcineurin inhibitors in children post‐liver transplantation

  2002cited by this paper
• Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.

  2002cited by this paper
• Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

  2002cited by this paper
• Sirolimus-based immunosuppressive [correction of immunosuppresive] protocol for calcineurin sparing in liver transplantation.

  2002cited by this paper
• Immunodulation of intestinal transplantation: antilymphocyte serum donor pretreatment vs. ex vivo graft irradiation.

  2002cited by this paper
• Basiliximab decreases the incidence of acute rejection after intestinal transplantation.

  2002cited by this paper
• Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement

  2002cited by this paper
• Calcineurin inhibitor‐induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent

  2002cited by this paper
• Mycophenolic Acid and Mycophenolic Acid Glucuronide Pharmacokinetics in Pediatric Liver Transplant Recipients: Effect of Cyclosporine and Tacrolimus Comedication

  2002cited by this paper
• Complete withdrawal of immunosuppression in living donor liver transplantation.

  2002cited by this paper
• Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin.

  2002cited by this paper
• Basiliximab reduces acute liver allograft rejection in pediatric patients.

  2002cited by this paper
• Effect of race on outcome of orthotopic liver transplantation: a cohort study.

  2002cited by this paper
• A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

  2002cited by this paper
• A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION

  2002cited by this paper
• First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.

  2002cited by this paper
• Intestinal transplantation before and after the introduction of sirolimus1

  2002cited by this paper
• Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children

  2002cited by this paper
• Liver transplant induction trial of daclizumab to spare calcineurin inhibition.

  2002cited by this paper
• New approaches to immunosuppression in liver transplantation

  2002cited by this paper
• Neoral C2 monitoring in pediatric liver transplant recipients

  2001cited by this paper
• Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin.

  2001cited by this paper
• USE OF MYCOPHENOLATE MOFETIL AS RESCUE THERAPY AFTER PEDIATRIC LIVER TRANSPLANTATION

  2001cited by this paper
• Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results.

  2001cited by this paper
• Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.

  2001cited by this paper
• Daclizumab induction in liver transplant recipients.

  2001cited by this paper
• From Beach to Bedside: History of the Development of Sirolimus

  2001cited by this paper
• Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

  2001cited by this paper
• WEANING OF IMMUNOSUPPRESSION IN LIVING DONOR LIVER TRANSPLANT RECIPIENTS1

  2001cited by this paper
• A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

  2001cited by this paper
• Experience with basiliximab in pediatric liver graft recipients.

  2001influential reference
• Neoral C(2) monitoring in pediatric liver transplant recipients.

  2001cited by this paper
• De novo use of low-dose tacrolimus and sirolimus in liver transplantation.

  2001cited by this paper
• Orthotopic liver transplantation using low‐dose tacrolimus and sirolimus

  2001cited by this paper
• A population pharmacokinetic screen to identify demographic‐clinical covariates of basiliximab in liver transplantation

  2001influential reference
• The Prevalence of Osteopenia in Pediatric Renal Allograft Recipients Varies with the Method of Analysis

  2001cited by this paper
• A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

  2001cited by this paper
• Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation.

  2001cited by this paper
• CALCINEURIN-INHIBITOR RELATED NEPHROTOXICITY- REVERSIBILITY IN PAEDIATRIC LIVER TRANSPLANT RECIPIENTS1

  2001cited by this paper
• Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients

  2001cited by this paper
• The genetic determinants of the CYP3A5 polymorphism.

  2001cited by this paper
• Reasons why some children receiving tacrolimus therapy require steroids more than 5 years post liver transplantation

  2001cited by this paper
• Liver transplantation using sirolimus and minimal corticosteroids (3‐day taper)

  2001cited by this paper
• Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.

  2000cited by this paper
• Sirolimus-tacrolimus combination immunosuppression.

  2000cited by this paper
• Isolated Intestinal Transplantation for Intestinal Failure

  2000cited by this paper
• Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

  2000cited by this paper
• A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.

  2000cited by this paper
• Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy.

  2000cited by this paper
• Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Fatal subfulminant hepatic failure with ofloxacin.

  2000cited by this paper
• Constructing a Prediction Interval for Time to Reach a Threshold Concentration Based on a Population Pharmacokinetic Analysis: An Application to Basiliximab in Renal Transplantation

  1999cited by this paper
• Early steroid withdrawal in liver transplantation is safe and beneficial.

  1999cited by this paper
• Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.

  1999cited by this paper
• Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.

  1999cited by this paper
• Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.

  1999cited by this paper
• Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis.

  1999cited by this paper
• New usage paradigms in antibody therapy: induction or true prophylaxis?

  1999cited by this paper
• Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

  1999cited by this paper
• Sirolimus: a potent new immunosuppressant for liver transplantation.

  1999cited by this paper
• Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

  1999cited by this paper
• Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.

  1999cited by this paper
• Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.

  1999cited by this paper
• Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

  1999cited by this paper
• Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  1999cited by this paper
• Basiliximab. Point of view

  1999cited by this paper
• Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

  1999cited by this paper
• Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.

  1999cited by this paper
• A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation.

  1999cited by this paper
• Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8).

  1999cited by this paper
• Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

  1999cited by this paper
• The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.

  1999cited by this paper
• Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update.

  1998cited by this paper
• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  1998cited by this paper

• Pediatric Liver Transplantation in Countries with Low Resources: Medical Issues Before and After Transplant

  2016cites this paper
• Small Bowel Transplantation: Is There a Hope on the Horizon?

  2015cites this paper
• Long-term outcomes after pediatric liver transplantation

  2013cites this paper
• Calcineurin Inhibitor Sparing in Paediatric Solid Organ Transplantation

  2012cites this paper
• Intestinal Transplantation in Children

  2011cites this paper
• Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients

  2011cites this paper
• Autoimmune cytopaenia after paediatric intestinal transplantation: a case series

  2010influential citation
• Corticosteroids usage in pediatric liver transplantation: To be or not to be!

  2009cites this paper
• Risk Factors for Rejection and Infection in Pediatric Liver Transplantation

  2008cites this paper
• Paediatric liver transplantation in New Zealand: the first 5 years.

  2007cites this paper
• Paediatric immunosuppression following solid organ transplantation

  2006cites this paper
• Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management

  2006cites this paper